At a glance
ClinicalIndex Comparison RecordN/ACompleted· 335 enrolled
Drug / intervention
clarithromycin modified release 500 mgdrug
Likely dose
clarithromycin modified release 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clarithromycin Modified Release Observational Study for Evaluation of Treatment, Tolerability & Recovery Time in Saudi & Egyptian Clinical Settings (CLOSER)
In Brief
An observational study evaluating clarithromycin modified release 500 mg for Respiratory Tract Infection. Completed, enrolled 335 participants across 12 sites in 2 countries.
Detailed Summary
The objective is to describe the time to recovery of symptoms (cough, mucus, fever, sore throat, and others), tolerability and compliance of treatment with clarithromycin once daily in patients with upper or lower respiratory tract infections in the routine clinical practice.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRespiratory Tract Infection
CountriesEgypt, Saudi Arabia
CollaboratorsEilaf
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2010
Enrollment StartJan 2011
Primary CompletionJan 2012
TodayJul 2026
First PostedFeb 25, 2010
Enrollment StartJan 1, 2011
Primary CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 16.4 years ago
Interventions
clarithromycin modified release 500 mgdrug
clarithromycin modified release 500 mg for 7 days